Industries de la santé
18 Mars 2016
NEW YORK, NY - 03/14/16 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers provided investors with an update on its business progress following the filing of its 2015 10-K. |Recent Highlights
· Received clearance from the FDA for...
Plus d'articles...
- Présentation de l'étude de Phase II CoFAR6 - sponsorisée par le NIH - NIAID confirmant de nouveau l'innocuité et l'efficacité de Viaskin® Peanut
- Teradata et Knowledgent s'associent pour aider les entreprises du secteur de la santé à mieux évaluer les risques liés aux patients
- Burgeoning Global Telehealth Market Could Deliver Huge Savings to Government Healthcare Budgets, says GBI Research
- Actinium Pharmaceuticals Selects Medpace Inc. as Clinical Research Organization for Pivotal Phase 3 Iomab-B Trial